Pulnovo Medical Reports Trial Results in New England Journal of Medicine
Pulnovo Medical announced findings from its PADN-HF-PH trial at ESC Congress 2026, published simultaneously in The New England Journal of Medicine. The study showed a significant reduction in clinical worsening risk for PH-LHD patients.
Pulnovo Medical has presented the clinical outcomes from its PADN-HF-PH trial at the European Society of Cardiology (ESC) Congress 2026. The results were simultaneously published in The New England Journal of Medicine.
The trial involved 264 patients diagnosed with PH-LHD. Data demonstrated a 51% reduction in the risk of clinical worsening among participants receiving the treatment. Furthermore, a 35.5% decrease in recurrent clinical events was observed.
The study also indicated sustained improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the company's pulmonary artery intervention. These findings highlight the potential of this approach for managing PH-LHD.
This publication provides significant new data for the treatment of pulmonary hypertension and its associated conditions. Pulnovo Medical continues its work to advance treatments and improve patient outcomes in this field.